Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
Earnings Data
Report Date
May 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.78Last Year’s EPS
0.78Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights strong commercial execution and clear momentum: record quarterly revenues (+21% YoY), robust cash generation ($348.2M) and a healthy cash balance ($882.5M); sustained patient adds and a reiterated blockbuster revenue guide for 2026 support a positive commercial outlook. The company is actively advancing a rich late-stage pipeline (5 Phase III programs) with multiple near-term catalysts (pitolisant GR NDA Q2 2026, pitolisant HD top line 2027, EPX-100 data H1 2027). Key challenges include a significant rise in operating expenses (~45% YoY), a near‑term drop in non-GAAP adjusted net income and EPS (~48% decline), ongoing ANDA litigation/IP uncertainty (one filer unresolved), and competitive/enrollment pressures in certain programs. Overall, achievements and forward-looking catalysts materially outweigh the risks, though litigation and elevated investment-driven expenses warrant monitoring.Company Guidance
Record Quarterly and Annual Revenues
Q4 2025 net product revenue of $243.8M, up 21% year-over-year from $201.3M; full year 2025 WAKIX net product revenue of $868.5M, marking the highest quarterly and strong annual performance.
Sustained Patient Growth
Q4 marked the third consecutive quarter with approximately 400+ average patient adds (first time in franchise history), bringing WAKIX to ~8,500 average patients and supporting further growth opportunity within an estimated 80,000 diagnosed narcolepsy patients.
Blockbuster Guidance for 2026
Company reiterated guidance for WAKIX net revenue of $1.00B to $1.04B for 2026 (first time guiding to blockbuster status for the franchise).
Strong Cash Generation and Balance Sheet
Generated $348.2M of cash from operations in 2025 and ended Q4 with $882.5M in cash, cash equivalents and investments, providing capacity to fund pipeline advancement and BD opportunities.
Pipeline Advancements and Multiple Near-Term Catalysts
Five ongoing Phase III registrational trials across distinct CNS indications; pitolisant GR on track for NDA submission in Q2 2026 with target PDUFA Q1 2027; pitolisant HD top-line data expected in 2027 (PDUFA 2028); EPX-100 registrational programs enrolling with top-line data expected H1 2027 (PDUFA 2028); orexin-2 agonist BP1.15205 Phase I PK data expected mid-2026.
Label Expansion — Pediatric Cataplexy
FDA approval (Feb 13, 2026) of WAKIX for treatment of cataplexy in patients ≥6 years old, expanding indication to pediatric population and advancing path toward pediatric exclusivity (an additional 6 months regulatory exclusivity).
IP and ANDA Litigation Progress
Settled with 6 of 7 ANDA filers; based on settlements, potential generic entry would be no sooner than March 2030 if pediatric exclusivity is obtained (company states it is on track to obtain it); company confident in IP and will continue to defend it.
Clinical Efficacy Signals in Epilepsy Asset
EPX-100 label-extension/OLE data showed clinically meaningful seizure reductions (~50% median reduction and ~50% of patients with ≥50% reduction after ≥6 months exposure) with generally favorable tolerability and no new monitoring requirements.
Commercial Investments and Execution
Commercial organization expanding field-based teams by ~20% (field sales >10%, field reimbursement >50%, remote sales >10%) and launching process improvements including a new patient portal to shorten time to dispense and boost conversion.
HRMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HRMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $26.87 | $28.19 | +4.91% |
Nov 04, 2025 | $29.33 | $30.72 | +4.74% |
Jul 31, 2025 | $35.48 | $35.18 | -0.85% |
May 06, 2025 | $29.96 | $32.05 | +6.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Harmony Biosciences Holdings (HRMY) report earnings?
Harmony Biosciences Holdings (HRMY) is schdueled to report earning on May 05, 2026, Before Open (Confirmed).
What is Harmony Biosciences Holdings (HRMY) earnings time?
Harmony Biosciences Holdings (HRMY) earnings time is at May 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRMY EPS forecast?
HRMY EPS forecast for the fiscal quarter 2026 (Q1) is 0.78.